Sanofi, Boehringer Ingelheim’s asset swap : Why and How?
Sanofi and Boehringer Ingelheim have agreed to a $25.1 billion asset swap, in which Sanofi will trade its Merial animal-health business for... Read More
Case Study: Hetero’s launch of Biosimilar ‘Bevacizumab’ Brand ‘Cizumab’ in India
Posted on28 Jun 2016
Comments0
Hetero, one of India’s leading generic pharmaceutical companies, today announces the launch of Biosimilar ‘Bevacizumab’ in India for the treatment of metastatic... Read More
Pfizer completes acquisitions of Anacor
Pfizer Inc. completed its acquisition of Anacor Pharmaceuticals, Inc. According to the company, the transaction terms provided each outstanding share of Anacor... Read More
Gilead’s single tablet regimen Odefsey got EU marketing authorization for HIV treatment
The European Commission has granted marketing authorization for Gilead Sciences’ once-daily single tablet regimen (STR) Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide... Read More
Affilogic announces partnership with Sanofi to develop Nanofitin-conjugated biotherapeutics
Posted on27 Jun 2016
Comments0
Affilogic, a privately-owned biotech company, announced the signature of a collaboration and license agreement with Sanofi, a global healthcare leader, for the... Read More
What is BREXIT? It’s impact in Pharmaceutical Industry : A Must Know for Pharma Professionals
Brexit is an abbreviation of “British exit”, which refers to the June 23, 2016 referendum by British voters to exit the European... Read More
Sanaofi’s Dengvaxia got 5th country approval – Costa Rica
Sanofi Pasteur, Sanofi’s vaccine division, announced that the National Ministry of Health of Costa Rica has approved Sanofi Pasteur’s tetravalent dengue vaccine,... Read More
Fycompa Brand Extension: Eisai Launched FYCOMPA® (perampanel) Oral Suspension
Fycompa Brand Extension: Eisai Launched FYCOMPA® (perampanel) Oral Suspension Brand: FYCOMPA® Molecule: perampanel. Indication: FYCOMPA (perampanel) is indicated as adjunctive therapy for... Read More
Novartis collaboration for KAF156 with Medicines for Malaria Venture (MMV)
Posted on16 Jun 2016
Comments0
Novartis AG, a Switzerland-based drug maker, announced that it will further expand its long-standing partnership with Medicines for Malaria Venture (MMV). Under the... Read More
FDA approves AspireAssist obesity device of Aspire Bariatrics
The U.S. Food and Drug Administration today approved a new obesity treatment device that uses a surgically-placed tube to drain a portion... Read More